TBG Diagnostics Limited.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TBG Diagnostics Limited.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Sibnayal, Advicenne’s innovative treatment for distal renal tubular acidosis, is set to be approved for use in the EU shortly.
Advanced breast cancer treatment Enhertu and non-small cell lung cancer and thyroid cancer therapy Retsevmo are set to win conditional marketing authorizations in the EU shortly. The two drugs are among a number of new products that the European Medicines Agency has just recommended for approval.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Epi Pharmaceuticals Inc. (EPI)
- PharmaSynth Pty Ltd
- Progen Industries Limited
- Progen Pharmaceuticals Limited
- Zhangsha ZhangYe Medical Laboratory Corp